We extend our sincere appreciation for the support of our corporate sponsors. Their generosity provides vital funding needed to fulfill our mission to make a lasting and positive difference in the lives of people who have kidney disease.
THANK YOU TO OUR CORPORATE PARTNERS
Fresenius Kidney Care, a division of Fresenius Medical Care North America (FMCNA), provides dialysis treatment and services to more than 190,000 people with kidney disease at more than 2,400 facilities nationwide. Fresenius Kidney Care supports people by helping to address both the physical and emotional aspects of kidney disease through personalized care, education and lifestyle support services so they can lead meaningful and fulfilling lives.
U.S. Renal Care serves more than 23,000 patients in 300 dialysis facilities in 31 states and the Territory of Guam with a unique business model, developing and operating dialysis centers in joint venture partnerships with leading local nephrologists.
Akebia Therapeutics is a biopharmaceutical company with the purpose to better the life of each person impacted by kidney disease. We have both a commercially available product and a potential first-in-class product candidate for the treatment of anemia due to chronic kidney disease. We are located in the biotech hub of Cambridge, Massachusetts, where we are inspired by our peers and dedicated to working with our partners, patients, advocacy organizations and the broader kidney community.
Amgen is one of the world’s leading biotechnology companies. Amgen is a values-based company, deeply rooted in science and innovation to transform new ideas and discoveries into medicines for patients with serious illnesses.
Astrazenca is a global, science-led biopharmaceutical business whose innovative medicines are used by millions of patients worldwide.
DaVita is a leading provider of dialysis services to patients with chronic kidney failure and end stage renal disease.
CSL Vifor is a global partner of choice for innovative therapies in iron deficiency, dialysis and nephrology & rare disease. We specialize in global partnering, in-licensing and commercializing products with the aim to help patients around the world lead better, healthier lives.
Transplant Genomics, Inc. (“TGI”) is a personalized diagnostics company committed to improving organ transplant outcomes worldwide through innovative tests that detect early signs of graft injury, differentiate among actionable causes, and enable the optimization of therapy. Working alongside the transplant community and within the Eurofins family, TGI is commercializing a suite of tests enabling diagnoses and prediction of transplant recipient immune status. TGI was acquired by Eurofins in 2019. Learn more about Transplant Genomics